Karyopharm Therapeutics (KPTI) Stock Price
$4.95 0%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
2 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Karyopharm Therapeutics, AI stock picks, stock alerts and much more.
KPTI AI Stock Analysis
AI stock analysis for KPTI is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Karyopharm Therapeutics (KPTI) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Karyopharm Therapeutics (KPTI) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Karyopharm Therapeutics (KPTI), currently trading at $4.95, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About KPTI
-
Karyopharm Therapeutics Inc.
-
Symbol
KPTI
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
42.4M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$22.52 1.5% |
5 |
 |
Inovio Pharmaceuticals INO |
$1.74 1.2% |
1 |
 |
Moderna MRNA |
$24.72 1.9% |
3 |
 |
Anavex Life Sciences AVXL |
$8.95 1.2% |
5 |
 |
BridgeBio Pharma BBIO |
$33.87 0.1% |
4 |
News
KPTI Alternative Data
Web Traffic
Karyopharm Therapeutics receives an estimated 7506 monthly visitors to karyopharm.com.
-
Web Traffic
7506
-
Change from Previous Month
6.4%
-
3 Month Change
20.7%
-
YoY Change
20.7%
News Mentions
Karyopharm Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
Reddit Mentions
Karyopharm Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
Twitter Followers
Karyopharm Therapeutics has 1,552 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.
-
Twitter Followers
1552
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
0.1%
-
YoY Change
0.1%
LinkedIn Followers
34,433 are following Karyopharm Therapeutics on LinkedIn, up by 1.2% over the last month.
-
LinkedIn Followers
34433
-
Daily Change
0%
-
1 Month Change
1.2%
-
3 Month Change
3.2%
Job Postings
Karyopharm Therapeutics currenly has an estimated 10 open job postings, up by 42.9% over the last month.
-
Job Postings
10
-
Daily Change
0%
-
1 Month Change
42.9%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Karyopharm Therapeutics has 362 employees.
-
LinkedIn Employees
362
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
2.2%
-
YoY Change
2.2%
Facebook Engagement
Karyopharm Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Karyopharm Therapeutics is 65 out of 100 (bullish).
-
Business Outlook
65
-
Change from Previous Month
3.2%
-
3 Month Change
0%
-
YoY Change
0%
KPTI Financials
KPTI Key Metrics
-
Total Revenue
$30.5M
-
Net Income
-$30.8M
-
Earnings per Share
$0.0924
-
Free cash flow
-$25.8M
-
EBITDA
-$19.6M
-
EBITDA Ratio
-0.64187
-
Total Assets
$164.4M
KPTI 2-year Revenue & Income
KPTI 2-year Free Cash Flow
KPTI Technicals
KPTI SMA
KPTI RSI
FAQ
What's the current price of Karyopharm Therapeutics (KPTI) Stock?
The price of an Karyopharm Therapeutics (KPTI) share is $4.95.
What's the market cap of Karyopharm Therapeutics?
The current market cap of Karyopharm Therapeutics is 42.4M.
Should I buy or sell KPTI?
Karyopharm Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Karyopharm Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Karyopharm Therapeutics a good investment?
The current analysis of Karyopharm Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Karyopharm Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Karyopharm Therapeutics (KPTI) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Karyopharm Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Karyopharm Therapeutics (KPTI) that investors often compare it to?
Karyopharm Therapeutics (KPTI) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Karyopharm Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Karyopharm Therapeutics' stock price to be around $4.89 in 2026. Starting from the current price of $4.95, this represents a 1.2% change in price, indicating a neutral outlook for the stock.
How to buy Karyopharm Therapeutics (KPTI) Stock?
Karyopharm Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Karyopharm Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.